Core Viewpoint - Rosen Law Firm is reminding investors who purchased Bitfarms Ltd. securities between March 21, 2023, and December 9, 2024, of the July 8, 2025, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Bitfarms securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by July 8, 2025 [2]. - The lawsuit alleges that Bitfarms made false and misleading statements regarding its financial reporting and internal controls, leading to inaccurate financial statements that may need to be restated [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [3]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of West Pharmaceutical Services, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on July 7, 2025 [1] Group 1: Class Action Details - Investors who bought West common stock between February 16, 2023, and February 12, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6] - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [4] Group 2: Case Allegations - The lawsuit alleges that West Pharmaceutical Services made false and misleading statements regarding its business operations, particularly concerning its High-Value Products portfolio and the SmartDose device [5] - Specific claims include that West was experiencing significant destocking in its high-margin products, contrary to its public statements, and that operational inefficiencies were negatively impacting profit margins [5] - The lawsuit asserts that these misleading statements led to investor damages when the true situation was revealed [5]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Open Lending Corporation securities between February 24, 2022, and March 31, 2025, of the June 30, 2025, lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Open Lending securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 30, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Rosen Law Firm has been recognized for its performance in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. Group 3: Case Allegations - The lawsuit alleges that Open Lending's defendants made materially false and misleading statements and failed to disclose adverse facts about the company's business and operations [5]. - Specific allegations include misrepresentations regarding the capabilities of Open Lending's risk-based pricing models and misleading statements about profit share revenue [5]. - The lawsuit claims that the true details about the company's performance led to investor damages when revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Iovance Biotherapeutics, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on July 14, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - The class action lawsuit claims that Iovance made false and misleading statements regarding the effectiveness of its new Authorized Treatment Centers (ATCs) and the treatment timelines for its product Amtagvi, leading to higher costs and lower revenue [3]. - Investors who purchased Iovance securities between May 9, 2024, and May 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [4]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [4].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of UroGen Pharma Ltd. securities between July 27, 2023, and May 15, 2025, due to alleged misleading statements regarding the effectiveness of UroGen's lead pipeline product, UGN-102 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that UroGen made false and misleading statements about the ENVISION clinical study, which lacked a concurrent control arm, affecting the demonstration of UGN-102's effectiveness [5]. - It is alleged that UroGen ignored FDA warnings about the study design, leading to a substantial risk that the New Drug Application (NDA) for UGN-102 would not be approved [5]. - The lawsuit asserts that when the true details were revealed, investors suffered damages due to the misleading nature of UroGen's positive statements about its business and prospects [5]. Group 2: Participation Information - Investors who purchased UroGen securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm directly for more information [3][6].

Core Viewpoint - Rosen Law Firm has filed a class action lawsuit on behalf of purchasers of Red Cat Holdings, Inc. securities between March 18, 2022, and January 15, 2025, alleging misleading statements regarding production capacity and contract value [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Red Cat Holdings made false and misleading statements about the production capacity of its Salt Lake City Facility and the overall value of the SRR Contract [5]. - Investors who purchased Red Cat securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. Group 2: Participation Information - Interested parties can join the class action by visiting the provided link or contacting Phillip Kim, Esq. for more information [3][6]. - A lead plaintiff must move the Court by July 22, 2025, to represent other class members in the litigation [1][3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and recovering hundreds of millions for investors [4]. - The firm has been consistently ranked among the top firms for securities class action settlements since 2013, securing over $438 million for investors in 2019 alone [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased NET Power Inc. securities between June 9, 2023, and March 7, 2025, of the upcoming lead plaintiff deadline on June 17, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought NET Power securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by June 17, 2025 [2]. - The lawsuit alleges that NET Power made false and misleading statements regarding Project Permian, including the likelihood of completing the project on schedule and the associated costs [3]. Group 2: Allegations Against NET Power - The lawsuit claims that NET Power was unlikely to complete Project Permian on time and that the project would be significantly more expensive due to supply chain issues and site-specific challenges [3]. - It is asserted that the projections regarding the time and capital needed for Project Permian were unrealistic, which could negatively impact NET Power's business and financial results [3]. - The public statements made by NET Power were deemed materially false and misleading, leading to investor damages when the true details became known [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time and has been ranked highly for its performance in this area since 2013 [4]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased NAPCO Security Technologies, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on June 24, 2025 [1]. Group 1: Class Action Details - Investors who purchased NAPCO securities between February 5, 2024, and February 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by June 24, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that NAPCO made false and misleading statements regarding its revenue outlook and growth potential, downplaying risks associated with seasonality and macroeconomic factors [5]. - It is claimed that NAPCO's optimistic margin growth goals were unrealistic, as the company was not adequately prepared to forecast demand for its products [5].

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Organon & Co. (NYSE: OGN) between October 31, 2024 and April 30, 2025, both dates inclusive (the “Class Period”), of the important July 22, 2025 lead plaintiff deadline. SO WHAT: If you purchased Organon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

NEW YORK, June 05, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) between May 9, 2024 and May 8, 2025, both dates inclusive (the “Class Period”), of the important July 14, 2025 lead plaintiff deadline. SO WHAT: If you purchased Iovance securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...